Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients

Authors:

Abstract
The efficacy and safety of lipid‐lowering agents in elderly individuals have not been extensively assessed. This population generally takes more drugs concurrently than middle‐aged patients, and are therefore at higher risk of drug‐drug interactions. This large‐scale, randomized, double‐blind, placebo‐controlled study investigated the efficacy and safety of extended‐release (XL) fluvastatin 80 mg once daily for up to 1 year in elderly patients with primary hypercholesterolemia. A total of 1229 patients (mean age, 75.5 years) were randomized. After 2 months of treatment, fluvastatin XL 80 mg significantly decreased plasma lipid levels from baseline compared with placebo; fluvastatin reduced total cholesterol by 25% compared with a decrease of 2.5% in the placebo group, low‐density lipoprotein cholesterol was −33% vs. −2.5%, respectively, and triglycerides were −13.3% vs. 2.9%, respectively (p

This publication has 24 references indexed in Scilit: